EGFR and prostate cancer: Similarly, pre-targeting LNCaP prostate cancer cells reached almost 3-fold improvement with PSMA BsAbs and 4-fold improvement with EGFR BsAbs compared to pre-mixing (Figures 2C, 2D, and S1F).